To mitigate tumor invasion and progression, CAR has been engineered to direct macrophages toward CCR7-positive tumor cells, which are part of a lipid droplet high (LDhi)CCR7hi immunosuppressive cell population [66] (Table 2). The gene discussed is CCR7; the disease is neoplasm.